Re: HGU133Plus2 CDF vs hgu133plus2hsentrezgcdf CDF (30% difference in results)
Marcin Cieślik <[email protected]> Mon, 15 Sep 2014 18:30:25 -0400
| Newsgroups | gmane.science.biology.informatics.conductor |
|---|---|
| Message-ID | <CAC5XLNeHj4_fBk59NSjxRkx40Qubukp2fMRBmszugj79=yuZag@mail.gmail.com> |
Hi All, > you could re-align the probe sequences against the current genome and see how many are still measuring the intended target. I have done this recently for the human agilent whole-genome array. I strongly suggest a spliced aligner (STAR worked very well). Bottom line the number of probes mapped to a gene with an ENSEMB id or approved symbol actually increased. Yours, Marcin On Mon, Sep 15, 2014 at 10:58 AM, James W. MacDonald <[email protected]> wrote: > Another thing to consider is that the probesets for that array are based on > UniGene build 133, which was current somewhere around 10 years ago (if not > longer). That is a long time ago, considering the speed with which the > human genome has been updated, so there may be many probesets on that array > that no longer measure anything recognizable. > > If you care to find out how bad (or good) the conventional Affymetrix > probeset definitions are, you could re-align the probe sequences against > the current genome and see how many are still measuring the intended > target. Or you could assume that the updated alignments from MBNI are > better, and just go with that (certainly easier, but you know what they say > about assumptions...). > > Personally, I would go with option A, which would have two benefits. One, > you would get to have some fun learning how to do something different. And > really, who doesn't like that? Two, it would give you a rock-solid > rationale for your choice of CDF, which should be impressive to your > advisor because you a) thought about the problem and then b) did something > to actively quantify the differences, so you can make an informed choice. > > Best, > > Jim > > > > On Sun, Sep 14, 2014 at 9:51 AM, Steve Lianoglou <lianoglou.steve-RuTDbSqP/[email protected] > > > wrote: > > > Hi, > > > > On Sat, Sep 13, 2014 at 11:31 AM, Mahes Muniandy [guest] > > <[email protected]> wrote: > > > Hello, > > > My name is Mahes Muniandy and I am a doctoral student. I have been > > analysing Affymetrix HGU133Plus2 cel files to determine differential > > expressions in twin pairs (within pair differences). I have used affy, > > gcrma, nsfilter and limma to do my analysis. I have run my analysis using > > the HGU133plus2 CDF available in biocondutor and then tried the whole > > analysis again using the HGU133plus2 cdf from Brainarray. The limma > results > > differ significantly (2351 differentially expressed genes for the former > > and 2700 genes for the latter analysis). 630 genes (about 30%) from the > > 2351 genes do not exist in the list of 2700 genes. > > > > > > I have read "Evolving Gene/Transcript Definitions Significantly Alter > > the Interpretation of GeneChip Data M. Dai et al." and see some > > convincing arguments there. But, I am confused with which limma results > to > > go with. Could you advise me on the guiding principles that I should > follow > > in order to decide which cdf to use. I do realise that the onus is on me > to > > decide but sadly, I am quite lost in this matter. I would appreciate any > > help available. > > > > I'd start by investigating whether or not the genes included in one > > analysis and not the other seem reasonable for your experiment (ie. do > > some GO analysis on the differences and see if they are relevant to > > the data/treatment you are studying). > > > > Another thing to check is to plot the t-statistics against each other > > from each analysis. Is the result you are finding a result of genes > > dancing around thresholds of significance? If you define significance > > by a certain FDR *and* a minimum absolute log-fold-change, it might be > > that you have better concordance -- when this too isn't perfect > > concordance, I'd go back and start looking at the differing genes and > > try to interpret the differences to see which makes more sense than > > the other. > > > > HTH, > > -steve > > > > -- > > Steve Lianoglou > > Computational Biologist > > Genentech > > > > _______________________________________________ > > Bioconductor mailing list > > [email protected] > > https://stat.ethz.ch/mailman/listinfo/bioconductor > > Search the archives: > > http://news.gmane.org/gmane.science.biology.informatics.conductor > > > > > > -- > James W. MacDonald, M.S. > Biostatistician > University of Washington > Environmental and Occupational Health Sciences > 4225 Roosevelt Way NE, # 100 > Seattle WA 98105-6099 > > [[alternative HTML version deleted]] > > _______________________________________________ > Bioconductor mailing list > [email protected] > https://stat.ethz.ch/mailman/listinfo/bioconductor > Search the archives: > http://news.gmane.org/gmane.science.biology.informatics.conductor > [[alternative HTML version deleted]] _______________________________________________ Bioconductor mailing list [email protected] https://stat.ethz.ch/mailman/listinfo/bioconductor Search the archives: http://news.gmane.org/gmane.science.biology.informatics.conductor